摘要
目的探讨周剂量紫杉醇与紫杉醇联合顺铂方案对局部晚期非小细胞肺癌(NSCLC)同步放化疗疗效的影响及毒性反应。方法收集接受同步放化疗的60例局部晚期NSCLC患者(Ⅲa期27例,Ⅲb期33例)的临床资料,其中30例患者接受周剂量紫杉醇方案,30例患者接受紫杉醇联合顺铂方案。2组放疗均采用常规分割放疗。分析不同化疗方案对患者总生存期和毒副反应发生率的影响。结果 2组患者的中位生存时间及1、2年总生存率均无显著差异(P=0.801)。2组毒副反应差异有统计学意义(P<0.05)。2组患者治疗前后KPS评分改善率、体质量增加比较,差异有统计学意义(P<0.05)。结论局部晚期NSCLC同步放化疗中,周剂量紫杉醇与紫杉醇联合顺铂(TP)方案可取得相似的疗效,但其血液学毒性、消化道反应的发生率较低,患者耐受性更好。
Objective To explore the efficacy and toxicity of concurrent chemoradiotherapy combined with low dose weekly paclitaxel or TP（paclitaxel and cisplatin）in treatment of local advanced non-small-cell lung cancer（LA-NSCLC）.Methods 60 patients with LANSCLC（27cases ofⅢ a stage,33 cases of Ⅲb stage）were randomly divided into low dose weekly paclitaxel group and TP group.All patients received conventional fractionation radiotherapy.The effect of different chemotherapy regimens on overall survival and toxicity was analyzed.Results The median survival time were 14.0months and 15.8months（P〈0.05）respectively in the two groups,and the overall 1-and 2-year survival rates were 63.3% and 36.7%,64.5%and 29.0%respectively（P=0.801）.There were no significant differences of radio-pneumonia,radio-esophagitis,liver and kidney dysfunction rate between two groups.Conclusion Compare with paclitaxel and cisplatin,concurrent chemotherapy with low dose paclitaxel administered in a weekly schedule is effective and well tolerated in patients with LA-NSCLC.
出处
《实用临床医药杂志》
CAS
2014年第19期30-33,共4页
Journal of Clinical Medicine in Practice
关键词
非小细胞肺癌
同步放化疗
周剂量
紫杉醇
non-small cell lung cancer
concurrent chemoradiotherapy
weekly dose
paclitaxel
